首页 > 最新文献

The American journal of the medical sciences最新文献

英文 中文
CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease. 基于 CT 的身体成分参数可预测克罗恩病患者对英夫利西单抗失去反应。
Pub Date : 2024-09-03 DOI: 10.1016/j.amjms.2024.08.025
Shaotang Li, Hao Wu, Shouliang Miao, Chen Huang, Yini Zhang, Xinyi Shao, Chao Chen, Xiaoli Wu

Objective: Infliximab is a first-line biologic agent for the treatment of Crohn's disease (CD), in which loss of response (LOR) remains a challenge in the treatment of patients with CD. The study aimed to explore the association between body composition parameters and LOR to infliximab in CD patients.

Methods: 118 patients with CD admitted to the First Affiliated Hospital of Wenzhou Medical University and treated with infliximab from June 2015 to December 2021 were retrospectively enrolled. The body composition of patients was analyzed by computed tomography (CT). The primary outcome measure was the one-year LOR. Patients were divided into the Remission group and the LOR group to analyze the association between body composition parameters and the LOR to infliximab.

Results: The rate of sarcopenia in the LOR group was higher than in the Remission group (83.7% vs. 60.0%, P=0.008). Multivariate analysis showed that females had a lower risk of sarcopenia than males (OR=0.30, 95%CI 0.11-0.81, P =0.017); BMI was significantly associated with sarcopenia (OR=0.68, 95%CI 0.56-0.83, P <0.001); L1 CD and L2 CD had a lower risk of sarcopenia than L3 CD (OR=0.29, 95%CI 0.10-0.83, P =0.021; OR=0.25, 95%CI 0.07-0.87, P=0.028).

Conclusions: Sarcopenia was identified as a risk factor for developing LOR in infliximab-treated patients.

目的:英夫利昔单抗是治疗克罗恩病(CD)的一线生物制剂:英夫利昔单抗是治疗克罗恩病(Crohn's disease,CD)的一线生物制剂。该研究旨在探讨身体成分参数与英夫利昔单抗治疗CD患者LOR之间的关系。方法:回顾性入选温州医科大学附属第一医院2015年6月至2021年12月收治的118例接受英夫利昔单抗治疗的CD患者。通过计算机断层扫描(CT)分析了患者的身体成分。主要结局指标为一年的LOR。患者被分为缓解组和LOR组,以分析身体成分参数与英夫利西单抗LOR之间的关系:结果:LOR组的肌少症发生率高于缓解组(83.7%对60.0%,P=0.008)。多变量分析显示,女性患肌肉疏松症的风险低于男性(OR=0.30,95%CI 0.11-0.81,P=0.017);体重指数与肌肉疏松症显著相关(OR=0.68,95%CI 0.56-0.83,P 结论:肌肉疏松症被认为是一种严重的慢性疾病:肌肉疏松症是英夫利西单抗治疗患者发生LOR的一个风险因素。
{"title":"CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease.","authors":"Shaotang Li, Hao Wu, Shouliang Miao, Chen Huang, Yini Zhang, Xinyi Shao, Chao Chen, Xiaoli Wu","doi":"10.1016/j.amjms.2024.08.025","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.025","url":null,"abstract":"<p><strong>Objective: </strong>Infliximab is a first-line biologic agent for the treatment of Crohn's disease (CD), in which loss of response (LOR) remains a challenge in the treatment of patients with CD. The study aimed to explore the association between body composition parameters and LOR to infliximab in CD patients.</p><p><strong>Methods: </strong>118 patients with CD admitted to the First Affiliated Hospital of Wenzhou Medical University and treated with infliximab from June 2015 to December 2021 were retrospectively enrolled. The body composition of patients was analyzed by computed tomography (CT). The primary outcome measure was the one-year LOR. Patients were divided into the Remission group and the LOR group to analyze the association between body composition parameters and the LOR to infliximab.</p><p><strong>Results: </strong>The rate of sarcopenia in the LOR group was higher than in the Remission group (83.7% vs. 60.0%, P=0.008). Multivariate analysis showed that females had a lower risk of sarcopenia than males (OR=0.30, 95%CI 0.11-0.81, P =0.017); BMI was significantly associated with sarcopenia (OR=0.68, 95%CI 0.56-0.83, P <0.001); L1 CD and L2 CD had a lower risk of sarcopenia than L3 CD (OR=0.29, 95%CI 0.10-0.83, P =0.021; OR=0.25, 95%CI 0.07-0.87, P=0.028).</p><p><strong>Conclusions: </strong>Sarcopenia was identified as a risk factor for developing LOR in infliximab-treated patients.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Onset Diabetic Ketoacidosis in a Renal Transplant Recipient. 肾移植受者新发糖尿病酮症酸中毒
Pub Date : 2024-08-28 DOI: 10.1016/j.amjms.2024.08.023
Havird McLean Skalak, Kaitlyn Haas, Melissa Laub, Laura L Mulloy

Post-transplant diabetes mellitus (PTDM) is a well-known solid organ transplant complication, which can be related to immunosuppressants, particularly tacrolimus. We report an unusual presentation of PTDM with diabetic ketoacidosis (DKA). This is unique as PTDM typically resembles Type 2 DM, whereas DKA is associated with Type 1 DM and has rarely been reported as a complication of tacrolimus. A 38-year-old African American male on LCP-tacrolimus presented four months post kidney transplant with vomiting, weakness, poor appetite, and polyuria. Labs demonstrated hyperglycemia, ketonuria, and high anion gap metabolic acidosis. He was nonobese and had no personal or family history of Type 2 DM. DKA was suspected to be secondary to tacrolimus-induced pancreatic beta cell damage worsened by supratherapeutic tacrolimus levels. Latent autoimmune diabetes in adults (LADA) was diagnosed when further testing showed insulinopenia, low C-peptide, and anti-glutamic acid decarboxylase (GAD) autoantibodies. He required 120-units of subcutaneous insulin daily. Our literature review revealed only 16 other tacrolimus-induced DKA cases. No cases reported anti-GAD positivity and most showed beta cell toxicity reversibility with tacrolimus tapering or substitution. Our patient was early post-transplant with leukocytopenia, so tacrolimus was not exchanged. This unusual PTDM case may have resulted from both autoimmune and tacrolimus-induced beta cell destruction. Physicians should be aware of new onset LADA post-transplantation and tacrolimus toxicity leading to DKA, even in patients without traditional risk factors. Anti-GAD antibody screening in patients on tacrolimus who develop PTDM may identify patients less likely to recover beta cell function with immunosuppression augmentation which requires careful monitoring.

移植后糖尿病(PTDM)是一种众所周知的实体器官移植并发症,可能与免疫抑制剂,尤其是他克莫司有关。我们报告了一种伴有糖尿病酮症酸中毒(DKA)的 PTDM 异常表现。这是一个独特的病例,因为 PTDM 通常类似于 2 型糖尿病,而 DKA 则与 1 型糖尿病有关,并且很少有作为他克莫司并发症的报道。一名服用 LCP-他克莫司的 38 岁非裔美国男性在肾移植术后四个月出现呕吐、乏力、食欲不振和多尿。实验室检查显示他患有高血糖、酮尿和高阴离子间隙代谢性酸中毒。他并不肥胖,也没有2型糖尿病的个人或家族病史。疑似继发于他克莫司诱发的胰腺β细胞损伤,而过高的他克莫司治疗水平又加重了胰腺β细胞损伤。当进一步检测发现胰岛素分泌减少、低C肽和抗谷氨酸脱羧酶(GAD)自身抗体时,他被诊断为成人潜伏性自身免疫性糖尿病(LADA)。他每天需要皮下注射 120 单位的胰岛素。我们查阅文献后发现,他克莫司诱发的 DKA 病例仅有 16 例。没有任何病例报告抗 GAD 阳性,大多数病例显示,他克莫司减量或替代后β细胞毒性可逆。我们的患者在移植后早期出现白细胞减少,因此没有更换他克莫司。这种不寻常的 PTDM 病例可能是由于自身免疫和他克莫司引起的β细胞破坏造成的。医生应注意移植后新发的 LADA 和他克莫司毒性导致的 DKA,即使患者没有传统的风险因素。在使用他克莫司并出现 PTDM 的患者中进行抗 GAD 抗体筛查,可以发现在加强免疫抑制的情况下不太可能恢复 β 细胞功能的患者,这就需要进行仔细监测。
{"title":"New Onset Diabetic Ketoacidosis in a Renal Transplant Recipient.","authors":"Havird McLean Skalak, Kaitlyn Haas, Melissa Laub, Laura L Mulloy","doi":"10.1016/j.amjms.2024.08.023","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.023","url":null,"abstract":"<p><p>Post-transplant diabetes mellitus (PTDM) is a well-known solid organ transplant complication, which can be related to immunosuppressants, particularly tacrolimus. We report an unusual presentation of PTDM with diabetic ketoacidosis (DKA). This is unique as PTDM typically resembles Type 2 DM, whereas DKA is associated with Type 1 DM and has rarely been reported as a complication of tacrolimus. A 38-year-old African American male on LCP-tacrolimus presented four months post kidney transplant with vomiting, weakness, poor appetite, and polyuria. Labs demonstrated hyperglycemia, ketonuria, and high anion gap metabolic acidosis. He was nonobese and had no personal or family history of Type 2 DM. DKA was suspected to be secondary to tacrolimus-induced pancreatic beta cell damage worsened by supratherapeutic tacrolimus levels. Latent autoimmune diabetes in adults (LADA) was diagnosed when further testing showed insulinopenia, low C-peptide, and anti-glutamic acid decarboxylase (GAD) autoantibodies. He required 120-units of subcutaneous insulin daily. Our literature review revealed only 16 other tacrolimus-induced DKA cases. No cases reported anti-GAD positivity and most showed beta cell toxicity reversibility with tacrolimus tapering or substitution. Our patient was early post-transplant with leukocytopenia, so tacrolimus was not exchanged. This unusual PTDM case may have resulted from both autoimmune and tacrolimus-induced beta cell destruction. Physicians should be aware of new onset LADA post-transplantation and tacrolimus toxicity leading to DKA, even in patients without traditional risk factors. Anti-GAD antibody screening in patients on tacrolimus who develop PTDM may identify patients less likely to recover beta cell function with immunosuppression augmentation which requires careful monitoring.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication-induced Fractures: Screening and Treatment Strategies. 药物诱发骨折:筛查和治疗策略。
Pub Date : 2024-08-28 DOI: 10.1016/j.amjms.2024.08.024
Laraib Javed, Aemen Khakwani, Uzair Khan, Mary Beth Humphrey

Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies.

药物引起的骨质疏松症导致大量骨折发病。随着多种药物的使用和美国人口的老龄化,预计与药物相关的骨折将大幅增加。导致骨质疏松症和骨折增加的最常见药物是糖皮质激素。其他许多疗法,包括襻利尿剂、SGLT2 抑制剂、噻唑烷二酮类、质子泵抑制剂、选择性血清素再摄取抑制剂、肝素、华法林、抗癫痫药、芳香化酶抑制剂、抗雄激素疗法、促性腺激素释放激素拮抗剂和钙神经蛋白抑制剂都与骨折风险增加有关。在此,我们回顾了这些药物的最新骨折风险证据,并讨论了骨折风险筛查和管理策略。
{"title":"Medication-induced Fractures: Screening and Treatment Strategies.","authors":"Laraib Javed, Aemen Khakwani, Uzair Khan, Mary Beth Humphrey","doi":"10.1016/j.amjms.2024.08.024","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.024","url":null,"abstract":"<p><p>Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Risk Factors for the Diagnosis of Insomnia in End-Stage Renal Disease. 诊断终末期肾病患者失眠症的心血管风险因素。
Pub Date : 2024-08-27 DOI: 10.1016/j.amjms.2024.08.022
Kiana Kim, Katlyn Smaha, Jennifer L Waller, Wendy B Bollag, Stephanie L Baer, Varsha Taskar, Vishal Arora, William Healy

Background: Insomnia, a known cardiovascular risk factor, is common in end-stage renal disease (ESRD) patients. There is growing acknowledgment of a potential bidirectional relationship between cardiovascular diseases and sleep disorders. We previously assessed the risk factors for common sleep disorders in ESRD patients. This follow-up study assesses the demographic and clinical cardiovascular-related risk factors for insomnia diagnosis in ESRD patients, given their increased cardiovascular burden.

Methods: This study is a retrospective analysis of the United States Renal Data System to evaluate risk factors for insomnia diagnosis. All patients in the USRDS who started dialysis between 2005 and 2019 were eligible for inclusion. Demographic risk factors analyzed were age, race, sex, ethnicity, dialysis modality, and access type. Cardiovascular risk factors, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), were also evaluated.

Results: Female sex, OSA, CSA, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease, obesity, and hypertension were associated with an increased risk of insomnia. Increasing age, non-white race, Hispanic ethnicity, and catheter or other/peritoneal dialysis access type were associated with a decreased risk of an insomnia diagnosis.

Conclusion: Various cardiovascular diseases were independent risk factors for an insomnia diagnosis in this retrospective cohort. Further study is indicated to investigate potential mechanisms underlying this connection.

背景:失眠是一种已知的心血管风险因素,在终末期肾病(ESRD)患者中很常见。越来越多的人认识到心血管疾病与睡眠障碍之间存在潜在的双向关系。我们曾对 ESRD 患者常见睡眠障碍的风险因素进行过评估。鉴于 ESRD 患者的心血管负担加重,本后续研究评估了 ESRD 患者失眠诊断的人口统计学和临床心血管相关风险因素:本研究对美国肾脏数据系统进行了回顾性分析,以评估失眠诊断的风险因素。美国肾脏数据系统中 2005 年至 2019 年期间开始透析的所有患者均符合纳入条件。分析的人口风险因素包括年龄、种族、性别、民族、透析方式和通路类型。还评估了心血管风险因素,包括阻塞性睡眠呼吸暂停(OSA)和中枢性睡眠呼吸暂停(CSA):结果:女性、OSA、CSA、心肌梗塞、充血性心力衰竭、外周血管疾病、脑血管疾病、糖尿病、慢性阻塞性肺病、肥胖和高血压与失眠风险增加有关。年龄增加、非白人种族、西班牙裔以及导管或其他/腹膜透析通路类型与失眠诊断风险降低有关:结论:在这一回顾性队列中,各种心血管疾病是失眠诊断的独立风险因素。结论:在这一回顾性队列中,各种心血管疾病是导致失眠诊断的独立危险因素,需要进一步研究这种关联的潜在机制。
{"title":"Cardiovascular Risk Factors for the Diagnosis of Insomnia in End-Stage Renal Disease.","authors":"Kiana Kim, Katlyn Smaha, Jennifer L Waller, Wendy B Bollag, Stephanie L Baer, Varsha Taskar, Vishal Arora, William Healy","doi":"10.1016/j.amjms.2024.08.022","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.022","url":null,"abstract":"<p><strong>Background: </strong>Insomnia, a known cardiovascular risk factor, is common in end-stage renal disease (ESRD) patients. There is growing acknowledgment of a potential bidirectional relationship between cardiovascular diseases and sleep disorders. We previously assessed the risk factors for common sleep disorders in ESRD patients. This follow-up study assesses the demographic and clinical cardiovascular-related risk factors for insomnia diagnosis in ESRD patients, given their increased cardiovascular burden.</p><p><strong>Methods: </strong>This study is a retrospective analysis of the United States Renal Data System to evaluate risk factors for insomnia diagnosis. All patients in the USRDS who started dialysis between 2005 and 2019 were eligible for inclusion. Demographic risk factors analyzed were age, race, sex, ethnicity, dialysis modality, and access type. Cardiovascular risk factors, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), were also evaluated.</p><p><strong>Results: </strong>Female sex, OSA, CSA, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease, obesity, and hypertension were associated with an increased risk of insomnia. Increasing age, non-white race, Hispanic ethnicity, and catheter or other/peritoneal dialysis access type were associated with a decreased risk of an insomnia diagnosis.</p><p><strong>Conclusion: </strong>Various cardiovascular diseases were independent risk factors for an insomnia diagnosis in this retrospective cohort. Further study is indicated to investigate potential mechanisms underlying this connection.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between cardiovascular health and serum vitamin D and its interaction with prediabetes and diabetes. 心血管健康与血清维生素 D 之间的关系及其与糖尿病前期和糖尿病的相互作用。
Pub Date : 2024-08-24 DOI: 10.1016/j.amjms.2024.08.021
Ying Chen, Haiyu Zhang, Yanbing Pan, Yanzi Zhang, Yuxuan Yang, Lu Liu, Qiuting Jia, Yongle Wang, Yihui Kong

Background: Prediabetes and diabetes are common and serious public health problems, and high blood glucose can lead to serious cardiovascular complications. The purpose of this article was to explore the link between CVH levels and the incidence of prediabetes and diabetes in people over 20 years old, and whether serum vitamin D status could alter this relationship.

Materials and methods: Data, from six consecutive cycles of the NHANES database from 2007 to 2018 were combined, eligible participants were aged ≥20 years. After excluding missing data, a total of 19,992 subjects were enrolled in the study. Significant risk factors for prediabetes and diabetes were analyzed using univariate and multivariate logistic regression. Exploring the interaction of VD and CVH on prediabetes and diabetes based on multifactorial regression analysis.

Results: The prevalence of prediabetes among all participants was 36.15% and the prevalence of diabetes was 16.39%. CVH and vitamin D levels are influential factors in prediabetes and diabetes, and are negatively associated with the risk of developing prediabetes and diabetes. Compared with normoglycemia, poorer CVH and vitamin D deficiency only had a synergistic multiplicative interaction on the development of diabetes, and no significant interaction was observed for the development of prediabetes. Compared with prediabetes, poorer CVH and vitamin D deficiency still had a synergistic additive interaction on the development of diabetes.

Conclusions: Although the cross-sectional study only determine the association and do not prove causality, the current results can be used to prompt people to improve their lifestyle and risk factors to prevent prediabetes or diabetes through higher CVH and adequate Vitamin D.

背景:糖尿病前期和糖尿病是常见的严重公共健康问题,高血糖可导致严重的心血管并发症。本文旨在探讨CVH水平与20岁以上人群糖尿病前期和糖尿病发病率之间的关系,以及血清维生素D状态是否会改变这种关系:数据来自2007年至2018年连续6个周期的NHANES数据库,符合条件的参与者年龄≥20岁。剔除缺失数据后,共有 19992 名受试者参与研究。采用单变量和多变量逻辑回归分析了糖尿病前期和糖尿病的重要风险因素。基于多因素回归分析,探讨 VD 和 CVH 对糖尿病前期和糖尿病的交互作用:所有参与者中糖尿病前期患病率为 36.15%,糖尿病患病率为 16.39%。CVH和维生素D水平是糖尿病前期和糖尿病的影响因素,与糖尿病前期和糖尿病的发病风险呈负相关。与正常血糖相比,较差的 CVH 和维生素 D 缺乏对糖尿病的发生只有协同的乘法相互作用,而对糖尿病前期的发生则没有观察到明显的相互作用。与糖尿病前期相比,较差的CVH和维生素D缺乏对糖尿病的发生仍有协同相加作用:虽然横断面研究只能确定两者之间的关联,并不能证明因果关系,但目前的研究结果可以用来提示人们改善生活方式和风险因素,通过较高的CVH和充足的维生素D来预防糖尿病前期或糖尿病。
{"title":"Association between cardiovascular health and serum vitamin D and its interaction with prediabetes and diabetes.","authors":"Ying Chen, Haiyu Zhang, Yanbing Pan, Yanzi Zhang, Yuxuan Yang, Lu Liu, Qiuting Jia, Yongle Wang, Yihui Kong","doi":"10.1016/j.amjms.2024.08.021","DOIUrl":"10.1016/j.amjms.2024.08.021","url":null,"abstract":"<p><strong>Background: </strong>Prediabetes and diabetes are common and serious public health problems, and high blood glucose can lead to serious cardiovascular complications. The purpose of this article was to explore the link between CVH levels and the incidence of prediabetes and diabetes in people over 20 years old, and whether serum vitamin D status could alter this relationship.</p><p><strong>Materials and methods: </strong>Data, from six consecutive cycles of the NHANES database from 2007 to 2018 were combined, eligible participants were aged ≥20 years. After excluding missing data, a total of 19,992 subjects were enrolled in the study. Significant risk factors for prediabetes and diabetes were analyzed using univariate and multivariate logistic regression. Exploring the interaction of VD and CVH on prediabetes and diabetes based on multifactorial regression analysis.</p><p><strong>Results: </strong>The prevalence of prediabetes among all participants was 36.15% and the prevalence of diabetes was 16.39%. CVH and vitamin D levels are influential factors in prediabetes and diabetes, and are negatively associated with the risk of developing prediabetes and diabetes. Compared with normoglycemia, poorer CVH and vitamin D deficiency only had a synergistic multiplicative interaction on the development of diabetes, and no significant interaction was observed for the development of prediabetes. Compared with prediabetes, poorer CVH and vitamin D deficiency still had a synergistic additive interaction on the development of diabetes.</p><p><strong>Conclusions: </strong>Although the cross-sectional study only determine the association and do not prove causality, the current results can be used to prompt people to improve their lifestyle and risk factors to prevent prediabetes or diabetes through higher CVH and adequate Vitamin D.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Useful biomarkers for predicting poor prognosis of patients with drug-induced liver injury: A retrospective cohort study. 预测药物性肝损伤患者不良预后的有用生物标志物:一项回顾性队列研究
Pub Date : 2024-08-23 DOI: 10.1016/j.amjms.2024.08.019
Hsueh-Chien Chiang, I-Chin Wu

Background: Drug-induced liver injury (DILI) plays an important role in liver failure and causes mortality. Patients with DILI compatible with Hy's law are associated with poorer outcomes. However, the predictive accuracy of Hy's law is not good enough in clinical practice. This study aimed to investigate the optimal values of biomarkers associated with the prognosis of DILI.

Methods: From June 1, 2014-May 30, 2022, patients with reported DILI were included. Patients' characteristics, drugs, DILI type, liver enzymes, and comorbidities were assessed. The associations with DILI-related comorbidities and survival were analyzed.

Results: Ninety-five DILI patients were enrolled, 5 patients died of liver failure, and 23 patients died within 56 weeks after DILI. This study found that 15 mg/dL of total bilirubin, 1000 U/L of ALT, and 2 of PT-INR were optimal cut-off values in predicting DILI-related mortality. For the overall survival, patients with sepsis (HR:5.053, 95% CI:1.594-16.018, p = 0.006), malignancy (HR:4.371, 95% CI:1.573-12.147, p = 0.005), or end-stage renal disease (HR:7.409, 95% CI:1.404-39.103, p = 0.018) were independent poor prognostic factors in multivariate Cox regression analysis.

Conclusions: Total bilirubin >15 mg/dL, ALT >1000 U/L, and PT-INR >2 are useful biomarkers in predicting DILI-related mortality. DILI patients with sepsis, malignancy, or end-stage renal disease are associated with worse overall survival.

背景:药物性肝损伤(DILI)在肝衰竭中起着重要作用,并导致死亡。符合海氏定律的 DILI 患者预后较差。然而,在临床实践中,Hy's 法则的预测准确性还不够好。本研究旨在探讨与DILI预后相关的生物标志物的最佳值:方法:纳入2014/06/01-2022/05/30期间报告的DILI患者。评估了患者的特征、药物、DILI类型、肝酶和合并症。分析了与DILI相关的合并症和存活率之间的关系:共有 95 名 DILI 患者入组,5 名患者死于肝功能衰竭,23 名患者在 DILI 后 56 周内死亡。研究发现,总胆红素 15 毫克/分升、谷丙转氨酶 1000U/L 和 PT-INR 2 是预测 DILI 相关死亡率的最佳临界值。在多变量考克斯回归分析中,脓毒症患者(HR:5.053,95%CI:1.594-16.018,P=0.006)、恶性肿瘤患者(HR:4.371,95%CI:1.573-12.147,P=0.005)或终末期肾病患者(HR:7.409,95%CI:1.404-39.103,P=0.018)是独立的不良预后因素:总胆红素>15 mg/dL、ALT>1000 U/L和PT-INR>2是预测DILI相关死亡率的有用生物标志物。伴有败血症、恶性肿瘤或终末期肾病的 DILI 患者总生存率较低。
{"title":"Useful biomarkers for predicting poor prognosis of patients with drug-induced liver injury: A retrospective cohort study.","authors":"Hsueh-Chien Chiang, I-Chin Wu","doi":"10.1016/j.amjms.2024.08.019","DOIUrl":"10.1016/j.amjms.2024.08.019","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced liver injury (DILI) plays an important role in liver failure and causes mortality. Patients with DILI compatible with Hy's law are associated with poorer outcomes. However, the predictive accuracy of Hy's law is not good enough in clinical practice. This study aimed to investigate the optimal values of biomarkers associated with the prognosis of DILI.</p><p><strong>Methods: </strong>From June 1, 2014-May 30, 2022, patients with reported DILI were included. Patients' characteristics, drugs, DILI type, liver enzymes, and comorbidities were assessed. The associations with DILI-related comorbidities and survival were analyzed.</p><p><strong>Results: </strong>Ninety-five DILI patients were enrolled, 5 patients died of liver failure, and 23 patients died within 56 weeks after DILI. This study found that 15 mg/dL of total bilirubin, 1000 U/L of ALT, and 2 of PT-INR were optimal cut-off values in predicting DILI-related mortality. For the overall survival, patients with sepsis (HR:5.053, 95% CI:1.594-16.018, p = 0.006), malignancy (HR:4.371, 95% CI:1.573-12.147, p = 0.005), or end-stage renal disease (HR:7.409, 95% CI:1.404-39.103, p = 0.018) were independent poor prognostic factors in multivariate Cox regression analysis.</p><p><strong>Conclusions: </strong>Total bilirubin >15 mg/dL, ALT >1000 U/L, and PT-INR >2 are useful biomarkers in predicting DILI-related mortality. DILI patients with sepsis, malignancy, or end-stage renal disease are associated with worse overall survival.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1,25-dihydroxyvitamin D mediated hypercalcemia in seminoma. 精原细胞瘤中由 1,25-二羟维生素 D 介导的高钙血症
Pub Date : 2024-08-22 DOI: 10.1016/j.amjms.2024.08.015
Julianna Sim, Jonathan Irvin, Nezam Altorok

Hypercalcemia has rarely been associated with seminomas. Due to the limited data available, the pathophysiology of hypercalcemia in seminoma has not been established in literature. We present a case of a 59-year-old male who presented with weakness, abdominal fullness, fatigue, constipation, and a 14 lb unintentional weight loss. On initial presentation he was found to be hypercalcemia with calcium of 16.2 mg/dL (normal 8.6-10.3 mg/dL). Subsequently, a metastatic seminoma was discovered with no evidence of bony metastasis. 1,25-dihydroxyvitamin D was elevated at >200 pg/mL (reference 19.9-79.3 pg/mL). PTH was suppressed at 11 pg/mL (reference 12-88 pg/mL). PTHrP was normal at 1.0 pmol/L (reference ≤4.2 pmol/L), 25‑hydroxy vitamin D was low at 22.6 ng/mL (reference 30-100 ng/mL), and phosphorus was normal at 3.9 mg/dL (reference 2.4-4.9 mg/dL). These findings indicate 1,25-dihydroxyvitamin D mediated hypercalcemia of malignancy. Hypercalcemia in seminoma has been reported in 11 cases, that we review in this report. However, few cases present sufficient data to conclude the pathophysiology of hypercalcemia. In all four cases that presented 1,25-hydroxyvitamin D levels, the levels were elevated, suggesting seminomas are associated with 1,25-hydroxyvitamin D mediated hypercalcemia. Interestingly, one case was associated with increased 1,25-hydroxyvitamin D and increased PTHrP levels, suggesting there may be multiple mechanisms of hypercalcemia in seminomas.

精索瘤很少伴有高钙血症。由于可用数据有限,精索瘤高钙血症的病理生理学尚未在文献中得到证实。我们报告了一例 59 岁男性患者的病例,该患者表现为乏力、腹部饱胀、疲倦、便秘,体重无意中减轻了 14 磅。初次就诊时,他被发现患有高钙血症,血钙为 16.2 毫克/分升(正常值为 8.6-10.3 毫克/分升)。随后发现了转移性精原细胞瘤,但没有骨转移的迹象。1,25-二羟维生素 D 升高,>200 pg/mL(参考值 19.9-79.3 pg/mL)。PTH 被抑制在 11 pg/mL(参考值 12-88 pg/mL)。PTHrP正常,为1.0 pmol/L(参考值≤4.2 pmol/L),25-羟基维生素D偏低,为22.6 ng/mL(参考值30-100 ng/mL),磷正常,为3.9 mg/dL(参考值2.4-4.9 mg/dL)。这些结果表明1,25-二羟维生素D介导的恶性肿瘤高钙血症。我们在本报告中回顾了 11 例精索瘤高钙血症病例。然而,很少有病例能提供足够的数据来对高钙血症的病理生理学做出结论。在所有四例出现 1,25-羟基维生素 D 水平升高的病例中,均表明精原细胞瘤与 1,25-羟基维生素 D 介导的高钙血症有关。有趣的是,其中一个病例的1,25-羟维生素D和PTHrP水平均升高,这表明精原细胞瘤可能存在多种高钙血症机制。
{"title":"1,25-dihydroxyvitamin D mediated hypercalcemia in seminoma.","authors":"Julianna Sim, Jonathan Irvin, Nezam Altorok","doi":"10.1016/j.amjms.2024.08.015","DOIUrl":"10.1016/j.amjms.2024.08.015","url":null,"abstract":"<p><p>Hypercalcemia has rarely been associated with seminomas. Due to the limited data available, the pathophysiology of hypercalcemia in seminoma has not been established in literature. We present a case of a 59-year-old male who presented with weakness, abdominal fullness, fatigue, constipation, and a 14 lb unintentional weight loss. On initial presentation he was found to be hypercalcemia with calcium of 16.2 mg/dL (normal 8.6-10.3 mg/dL). Subsequently, a metastatic seminoma was discovered with no evidence of bony metastasis. 1,25-dihydroxyvitamin D was elevated at >200 pg/mL (reference 19.9-79.3 pg/mL). PTH was suppressed at 11 pg/mL (reference 12-88 pg/mL). PTHrP was normal at 1.0 pmol/L (reference ≤4.2 pmol/L), 25‑hydroxy vitamin D was low at 22.6 ng/mL (reference 30-100 ng/mL), and phosphorus was normal at 3.9 mg/dL (reference 2.4-4.9 mg/dL). These findings indicate 1,25-dihydroxyvitamin D mediated hypercalcemia of malignancy. Hypercalcemia in seminoma has been reported in 11 cases, that we review in this report. However, few cases present sufficient data to conclude the pathophysiology of hypercalcemia. In all four cases that presented 1,25-hydroxyvitamin D levels, the levels were elevated, suggesting seminomas are associated with 1,25-hydroxyvitamin D mediated hypercalcemia. Interestingly, one case was associated with increased 1,25-hydroxyvitamin D and increased PTHrP levels, suggesting there may be multiple mechanisms of hypercalcemia in seminomas.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of mean heart rate on 30-day mortality in older patients with sepsis: Data from the MIMIC-IV database. 平均心率对老年败血症患者 30 天死亡率的影响:来自 MIMIC-IV 数据库的数据。
Pub Date : 2024-08-21 DOI: 10.1016/j.amjms.2024.08.006
Qiang Zhou, Jianing Li, Yuxiu Miao, Na Li

Background: Sepsis is a critical condition with a significant risk of mortality. Advanced age is one factor in increasing mortality in intensive care.

Objectives: The aim of this study is to investigate the association between mean heart rate (MHR) and 30-day mortality among older patients with sepsis in the intensive care unit (ICU).

Methods: All older patients (age 65 or older) with sepsis for first time in ICU admission in Medical Information Mart for Intensive Care-IV (MIMIC-IV) were included in this retrospective study. The effect of MHR within 24 h of ICU admission on 30-day mortality was assessed according to multivariable Cox regression models, restricted cubic splines and two-piecewise Cox regression models.

Results: The total number of participants was 6598 (mean heart rate, 83.8 ± 14.3 bpm). A total of 1295 (19.6%) patients died within 30 days after ICU admission. MHR within 24 h of admission was associated with 30-day mortality (J-shaped association) in older patients with sepsis in the ICU, with an inflection point at about 74 bpm and a minimal risk observed at 73 to 82 bpm of MHR.

Conclusions: In this retrospective cohort study, there was a J-shaped association between MHR and 30-day mortality in older patients with sepsis admitted to the ICU and a minimal risk observed at 73 to 82 bpm of MHR. If further confirmed, this association may provide a theoretical basis for formulating the target strategy of heart rate therapy for these patients.

背景:败血症是一种危重病,死亡率很高。高龄是增加重症监护死亡率的一个因素:本研究旨在调查重症监护室(ICU)中患有败血症的老年患者的平均心率(MHR)与 30 天死亡率之间的关系:这项回顾性研究纳入了重症监护医学信息市场-IV(MIMIC-IV)中所有首次入住重症监护室的老年脓毒症患者(65 岁或以上)。根据多变量 Cox 回归模型、限制性立方样条和双片式 Cox 回归模型评估了入院 24 小时内 MHR 对 30 天死亡率的影响:结果:参与研究的总人数为 6598 人(平均心率为 83.8±14.3 bpm)。共有 1295 名(19.6%)患者在入住 ICU 后 30 天内死亡。入院24小时内的MHR与重症监护室老年脓毒症患者30天内的死亡率有关(J形关联),拐点在74 bpm左右,MHR在73至82 bpm时风险最小:在这项回顾性队列研究中,入住重症监护室的老年脓毒症患者的 MHR 与 30 天死亡率呈 "J "形关联,MHR 在 73 至 82 bpm 时风险最小。如果得到进一步证实,这种关联可为制定这些患者的心率治疗目标策略提供理论依据。
{"title":"Effect of mean heart rate on 30-day mortality in older patients with sepsis: Data from the MIMIC-IV database.","authors":"Qiang Zhou, Jianing Li, Yuxiu Miao, Na Li","doi":"10.1016/j.amjms.2024.08.006","DOIUrl":"10.1016/j.amjms.2024.08.006","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a critical condition with a significant risk of mortality. Advanced age is one factor in increasing mortality in intensive care.</p><p><strong>Objectives: </strong>The aim of this study is to investigate the association between mean heart rate (MHR) and 30-day mortality among older patients with sepsis in the intensive care unit (ICU).</p><p><strong>Methods: </strong>All older patients (age 65 or older) with sepsis for first time in ICU admission in Medical Information Mart for Intensive Care-IV (MIMIC-IV) were included in this retrospective study. The effect of MHR within 24 h of ICU admission on 30-day mortality was assessed according to multivariable Cox regression models, restricted cubic splines and two-piecewise Cox regression models.</p><p><strong>Results: </strong>The total number of participants was 6598 (mean heart rate, 83.8 ± 14.3 bpm). A total of 1295 (19.6%) patients died within 30 days after ICU admission. MHR within 24 h of admission was associated with 30-day mortality (J-shaped association) in older patients with sepsis in the ICU, with an inflection point at about 74 bpm and a minimal risk observed at 73 to 82 bpm of MHR.</p><p><strong>Conclusions: </strong>In this retrospective cohort study, there was a J-shaped association between MHR and 30-day mortality in older patients with sepsis admitted to the ICU and a minimal risk observed at 73 to 82 bpm of MHR. If further confirmed, this association may provide a theoretical basis for formulating the target strategy of heart rate therapy for these patients.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating outcomes of transjugular intrahepatic portosystemic shunt procedure among Native Americans. 评估美国原住民经颈静脉肝内门体分流术的效果。
Pub Date : 2024-08-21 DOI: 10.1016/j.amjms.2024.08.008
Renxi Li, Shawn Sarin

Background: This study aims to explore racial disparities in immediate outcomes of Transjugular Intrahepatic Portosystemic Shunt (TIPS) among Native Americans, a group that have higher prevalence of liver cirrhosis but were the "invisible group" in previous TIPS studies due to their small population size.

Methods: The study identified Native Americans and Caucasians who underwent TIPS in National/Nationwide Inpatient Sample (NIS) database from Q4 2015-2020. Preoperative factors, including demographics, indications for TIPS, comorbidities, etiologies for liver disease, primary payer status, and hospital characteristics, were matched by 1:5 propensity score matching. In-hospital post-TIPS outcomes were then compared between the two cohorts.

Results: There were 6,658 patients who underwent TIPS, where 101 (1.52%) were Native Americans and 4,574 (68.70%) were Caucasians. Native Americans presented as younger, with a lower socioeconomic status, and displayed higher rates of alcohol abuse and related liver diseases. After propensity-score matching, Native Americans had comparable in-hospital post-TIPS outcomes including mortality (8.33% vs 9.09%, p = 1.00), hepatic encephalopathy (18.75% vs 25.84%, p = 0.19), acute kidney injury (28.13% vs 30.62%, p = 0.71), and other adverse events. Native Americans also had similar wait from admission to operation (2.15 ± 0.30 vs 2.87 ± 0.21 days, p = 0.13), hospital length of stay (7.43 ± 0.63 vs 8.62 ± 0.47 days, p = 0.13), and total costs (158,299 ± 14,218.2 vs 169,425 ± 8,600.7 dollars, p = 0.50).

Conclusion: Native Americans had similar immediate outcomes after TIPS compared to their propensity-matched Caucasians. While these results underscore effective healthcare delivery of TIPS to Native Americans, it is imperative to pursue further research for long-term post-procedure outcomes.

研究背景该研究旨在探讨经颈静脉肝内门体分流术(TIPS)近期疗效在美国原住民中的种族差异,美国原住民是肝硬化发病率较高的群体,但由于其人口规模较小,在以往的TIPS研究中属于 "隐形群体":该研究在 2015-2020 年第四季度的全国/全美住院病人样本(NIS)数据库中识别了接受 TIPS 的美国原住民和白种人。术前因素包括人口统计学、TIPS适应症、合并症、肝病病因、主要付款人身份和医院特征,通过1:5倾向评分匹配进行匹配。然后比较两组患者住院后的 TIPS 治疗效果:共有 6658 名患者接受了 TIPS,其中 101 名(1.52%)为美国本土人,4574 名(68.70%)为白种人。美国原住民年龄较轻,社会经济地位较低,酗酒和相关肝病的发病率较高。经过倾向分数匹配后,美国原住民住院后的TIPS结果相当,包括死亡率(8.33% vs 9.09%,p=1.00)、肝性脑病(18.75% vs 25.84%,p=0.19)、急性肾损伤(28.13% vs 30.62%,p=0.71)和其他不良事件。美国原住民从入院到手术的等待时间(2.15±0.30 vs 2.87±0.21天,P=0.13)、住院时间(7.43±0.63 vs 8.62±0.47天,P=0.13)和总费用(158299±14218.2 vs 169425±8600.7美元,P=0.50)也相似:结论:与倾向匹配的白种人相比,美国原住民在 TIPS 术后的近期疗效相似。虽然这些结果表明 TIPS 为美国本土居民提供了有效的医疗服务,但对术后长期疗效的进一步研究仍势在必行。
{"title":"Evaluating outcomes of transjugular intrahepatic portosystemic shunt procedure among Native Americans.","authors":"Renxi Li, Shawn Sarin","doi":"10.1016/j.amjms.2024.08.008","DOIUrl":"10.1016/j.amjms.2024.08.008","url":null,"abstract":"<p><strong>Background: </strong>This study aims to explore racial disparities in immediate outcomes of Transjugular Intrahepatic Portosystemic Shunt (TIPS) among Native Americans, a group that have higher prevalence of liver cirrhosis but were the \"invisible group\" in previous TIPS studies due to their small population size.</p><p><strong>Methods: </strong>The study identified Native Americans and Caucasians who underwent TIPS in National/Nationwide Inpatient Sample (NIS) database from Q4 2015-2020. Preoperative factors, including demographics, indications for TIPS, comorbidities, etiologies for liver disease, primary payer status, and hospital characteristics, were matched by 1:5 propensity score matching. In-hospital post-TIPS outcomes were then compared between the two cohorts.</p><p><strong>Results: </strong>There were 6,658 patients who underwent TIPS, where 101 (1.52%) were Native Americans and 4,574 (68.70%) were Caucasians. Native Americans presented as younger, with a lower socioeconomic status, and displayed higher rates of alcohol abuse and related liver diseases. After propensity-score matching, Native Americans had comparable in-hospital post-TIPS outcomes including mortality (8.33% vs 9.09%, p = 1.00), hepatic encephalopathy (18.75% vs 25.84%, p = 0.19), acute kidney injury (28.13% vs 30.62%, p = 0.71), and other adverse events. Native Americans also had similar wait from admission to operation (2.15 ± 0.30 vs 2.87 ± 0.21 days, p = 0.13), hospital length of stay (7.43 ± 0.63 vs 8.62 ± 0.47 days, p = 0.13), and total costs (158,299 ± 14,218.2 vs 169,425 ± 8,600.7 dollars, p = 0.50).</p><p><strong>Conclusion: </strong>Native Americans had similar immediate outcomes after TIPS compared to their propensity-matched Caucasians. While these results underscore effective healthcare delivery of TIPS to Native Americans, it is imperative to pursue further research for long-term post-procedure outcomes.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TPOAb Indicates neuroendocrine tumor in autoimmune gastritis: A retrospective study of 91 patients. 自身免疫性胃炎患者神经内分泌肿瘤的 TPOAb 指标:对 91 例患者的回顾性研究
Pub Date : 2024-08-21 DOI: 10.1016/j.amjms.2024.08.009
Bo Li, Honggang Jiang, Congbo Cai, Hongtan Chen

Background: The association between serological indexes and occurrence of complications in patients with autoimmune gastritis (AIG) remains unclear.

Methods: 91 patients with AIG were recruited and their clinical information were collected. The differences between serological indexes and complications of AIG were analyzed. And potential biomarker for early prediction and diagnosis of AIG with complications was explored.

Results: AIG patients in our study was 58.12 ± 11.68 years old, containing 31 males and 60 females. G17 was elevated in 49 of 52; PGI/II decreased in 43/49; GPA positive in 48/61; Anemia presented 28 in 80; Vitamin B12 deficiency occurred 23 in 58. Neuroendocrine tumor (NET) was the most common complication in AIG patients, accounting for 27/91. The second was polyps, making up for 14/91. There is also 9/91 of gastric mucosa neoplasia happened in AIG. No significant difference of G7, PGI, PGII, PGI/II and VB12 in AIG was found in different gastric mucosal lesions (P > 0.05). However, AIG patients with TPOAb positive had a higher risk in the occurrence of NET simultaneously (P = 0.0212). Those AIG with NET patients exhibited a significantly higher TPOAb level (P = 0.0078). ROC curve suggested that TPOAb can predict the existence of NET in AIG (AUC = 0.7410, P < 0.05).

Conclusion: We found that TPOAb can serve as a predictive biomarker of NET in AIG. This accessible test is helpful for endoscopy specialists to pay attention to gastric mucosal lesions in TPOAb-positive AIG patients, improving early diagnosis and intervention of comorbidities ability.

背景:方法:招募了91名自身免疫性胃炎(AIG)患者,并收集了他们的临床信息。分析血清学指标与 AIG 并发症之间的差异。分析血清学指标与 AIG 并发症之间的差异,探讨早期预测和诊断 AIG 并发症的潜在生物标志物:我们研究的 AIG 患者年龄为(58.12±11.68)岁,其中男性 31 人,女性 60 人。52例中有49例G17升高;43/49例PGI/II降低;48/61例GPA阳性;80例中有28例贫血;58例中有23例维生素B12缺乏。神经内分泌肿瘤(NET)是 AIG 患者最常见的并发症,占 27/91 例。其次是息肉,占 14/91。此外,有 9/91 的胃粘膜肿瘤发生在 AIG 患者身上。在不同的胃粘膜病变中,AIG 患者的 G7、PGI、PGII、PGI/II 和 VB12 均无明显差异(P > 0.05)。然而,TPOAb 阳性的 AIG 患者同时发生 NET 的风险更高(P = 0.0212)。AIG合并NET患者的TPOAb水平明显更高(P = 0.0078)。ROC曲线显示,TPOAb可预测AIG中NET的存在(AUC = 0.7410,P < 0.05):结论:我们发现 TPOAb 可作为 AIG 中 NET 的预测性生物标志物。结论:我们发现TPOAb可作为AIG中NET的预测性生物标志物,这种简便易行的检测方法有助于内镜专家关注TPOAb阳性AIG患者的胃黏膜病变,提高早期诊断和干预合并症的能力。
{"title":"TPOAb Indicates neuroendocrine tumor in autoimmune gastritis: A retrospective study of 91 patients.","authors":"Bo Li, Honggang Jiang, Congbo Cai, Hongtan Chen","doi":"10.1016/j.amjms.2024.08.009","DOIUrl":"10.1016/j.amjms.2024.08.009","url":null,"abstract":"<p><strong>Background: </strong>The association between serological indexes and occurrence of complications in patients with autoimmune gastritis (AIG) remains unclear.</p><p><strong>Methods: </strong>91 patients with AIG were recruited and their clinical information were collected. The differences between serological indexes and complications of AIG were analyzed. And potential biomarker for early prediction and diagnosis of AIG with complications was explored.</p><p><strong>Results: </strong>AIG patients in our study was 58.12 ± 11.68 years old, containing 31 males and 60 females. G17 was elevated in 49 of 52; PGI/II decreased in 43/49; GPA positive in 48/61; Anemia presented 28 in 80; Vitamin B12 deficiency occurred 23 in 58. Neuroendocrine tumor (NET) was the most common complication in AIG patients, accounting for 27/91. The second was polyps, making up for 14/91. There is also 9/91 of gastric mucosa neoplasia happened in AIG. No significant difference of G7, PGI, PGII, PGI/II and VB12 in AIG was found in different gastric mucosal lesions (P > 0.05). However, AIG patients with TPOAb positive had a higher risk in the occurrence of NET simultaneously (P = 0.0212). Those AIG with NET patients exhibited a significantly higher TPOAb level (P = 0.0078). ROC curve suggested that TPOAb can predict the existence of NET in AIG (AUC = 0.7410, P < 0.05).</p><p><strong>Conclusion: </strong>We found that TPOAb can serve as a predictive biomarker of NET in AIG. This accessible test is helpful for endoscopy specialists to pay attention to gastric mucosal lesions in TPOAb-positive AIG patients, improving early diagnosis and intervention of comorbidities ability.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The American journal of the medical sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1